# IMMP — Immutep Limited ADR · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** IMMP  
**Sources:** 23  
**Published:** 2026-08-05  
**Canonical:** https://app.k3vl4r.com/research/deep-research-immp-immutep-limited-adr-catalysts-narrative-risks-1549

---

# Immutep Limited ADR (IMMP) — Research Snapshot

*As of 2026-11-08. All figures and statements are drawn from cited sources and should be independently verified before any decision. This is not investment advice.*

## Company Context

Immutep Limited (ASX: IMM; Nasdaq: IMMP) is a clinical-stage biotechnology company headquartered in Sydney, Australia, developing LAG-3 (lymphocyte activation gene-3) immunotherapies for cancer and autoimmune diseases [[3]](https://www.immutep.com/investors-media/press-releases/). It was formerly Prima BioMed and changed its name in November 2017 [[27]](https://finance.yahoo.com/quote/IMMP/). CEO is Marc Voigt; CSO is Dr. Frédéric Triebel, who discovered LAG-3 [[25]](https://en.wikipedia.org/wiki/Immutep).

**Data-quality caveat:** The provided market-cap figure (~$24.61M as of 2026-11-08) conflicts with the CatalystAlert dossier's ~$39M as of 2026-07-22 [[1]](https://catalystalert.io/research/IMMP). Given Immutep's small float and thin liquidity, such discrepancies are plausible and worth watching.

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-immp-immutep-limited-adr-catalysts-narrative-risks-1549 (free to sign up)._